CTOs on the Move

Children's Crisis Treatment Center

www.cctckids.org

 
CCTC passionately serves the emotional needs of children and families at risk beginning in early childhood.
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.cctckids.org
  • 1080, North Delaware Avenue
    Philadelphia, PA USA 19125
  • Phone: 215.496.0707

Executives

Name Title Contact Details

Similar Companies

Your MedSource

Your MedSource is a Carrollton, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PolyPeptide Group

PolyPeptide Labs is a world leader in the manufacture of polypeptide, custom peptide Synthesis, peptide synthesis and generic peptide : generic GMP peptide and non-GMP peptide. PolyPeptide provides global support for a quality solution.

Talkiatry

Launched in April 2020, Talkiatry provides accessible in-network psychiatric care. The technology-driven service is committed to providing the highest level of mental health care on an outpatient basis. Based in New York City, Talkiatry offers seamless telehealth as well as in-person care in thoughtfully-designed, upscale offices—all at affordable, in-network prices. Talkiatry accepts a wide-range of insurance and employs psychiatrists and psychiatric nurse practitioners curated from among the city`s finest healthcare providers.

Amador Bioscience

Amador Bioscience, a leading partner for successful new drug development, provides global-standard translational sciences and clinical pharmacology services to clients ranging from cutting-edge biotech start-ups to multinational pharmaceutical companies. Founded in 2018 and supported by prominent institutional investors, Amador Bioscience operates in multiple sites, Pleasanton, CA, Ann Arbor, MI, Germantown, MD, Richmond, VA, Hangzhou and Shanghai, China, and Limburg.

Visus Therapeutics

Visus Therapeutics is a clinical-stage company in pursuit of developing the world`s first presbyopia-correcting eye drop with the potential to last at least eight hours. With offices in Seattle, Washington, and Orange County, California, our lead clinical candidate is VTI-001 (BRIMOCHOL™), a once-daily eye drop designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic product candidates.